Psychopharmacotherapy of Premenstrual Dysphoric Disorder- New Vistas
Affiliations
Affiliations
- Naguy, MBBch, MSc, Alamiri, MD, ABPN, ScD, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Prof. El-Sheshai, MD, PhD, Senior Professor of Psychiatry, and Consultant Psychiatrist, Alexandria Faculty of Medicine, Egypt. Thiguti, MD, MRCPsych, Consultant General Adult Psychiatrist, UK.
27 June 2022
Abstract
Nearly forty percent of women with PMDD remain impaired and resistant to first-line agents. This reflects complexity and heterogeneity of etiopathogenesis at the core of PMDD. Some agents, in the pipeline, sound promising that might usher in a new sparkle in the psychopharmacology of PMDD.
Keywords: PMDD; allopregnanolone; psychopharmacology.
Similar articles
Bixo M, Ekberg K, Poromaa IS, Hirschberg AL, Jonasson AF, Andréen L, Timby E, Wulff M, Ehrenborg A, Bäckström T.Psychoneuroendocrinology. 2017 Jun;80:46-55. doi: 10.1016/j.psyneuen.2017.02.031. Epub 2017 Mar 1.PMID: 28319848 Clinical Trial.
The pharmacotherapeutic management of premenstrual dysphoric disorder.
Ciccone N, Kovacheff MB, Frey BN.Expert Opin Pharmacother. 2023 Jan;24(1):145-151. doi: 10.1080/14656566.2022.2114345. Epub 2022 Aug 22.PMID: 35974667
Bixo M, Johansson M, Timby E, Michalski L, Bäckström T.J Neuroendocrinol. 2018 Feb;30(2). doi: 10.1111/jne.12553.PMID: 29072794 Review.
Bäckström T, Ekberg K, Hirschberg AL, Bixo M, Epperson CN, Briggs P, Panay N, O'Brien S.Psychoneuroendocrinology. 2021 Nov;133:105426. doi: 10.1016/j.psyneuen.2021.105426. Epub 2021 Sep 23.PMID: 34597899 Clinical Trial.
Premenstrual Dysphoric Disorder.
Lanza di Scalea T, Pearlstein T.Med Clin North Am. 2019 Jul;103(4):613-628. doi: 10.1016/j.mcna.2019.02.007.PMID: 31078196 Review.